Despite CBD’s popularity and increasing ubiquitousness, questions still linger regarding the safety and long-term impact of using hemp and cannabis-derived substance.
Since hemp is now legal and CBD is becoming more mainstream, the FDA has come under pressure to clarify its stance on the ingredient so manufacturers eager to capitalize on the growing demand can develop products that can be sold.
By Lauren Manning | March 2021
A summer 2019 study involving mice suggested that there may be a link between CBD and liver damage. Critics pushed for a human study, like Validcare’s, saying there are differences between how CBD functions in mice versus humans, and most people would not ingest the level of CBD provided to rodents in the study.
The results of the study are likely good news for players in the CBD industry who may have been fearing heavy restrictions, should the results have raised red flags.
There are still plenty of other health-related questions about CBD to tackle. These stem from the relative newness of the ingredient and the lack of long-term research on side effects or how it may interact with medications. As a result, the FDA has cracked down on CBD-containing products making health claims or statements about what the ingredient can accomplish.
Consumers are showing increasing eagerness to add CBD to their daily regimens, with 40% saying in March 2019 that they would try CBD, according to a study by High Yield Insights. The ingredient got a boost during the COVID-19 pandemic, as consumers sought ways to relax, ease tension and improve sleep quality.
Continue reading online.
